Showing results (211-220 of 265) with videos related to
Sort By:
Pageof 27
Journal of Cancer Research and Clinical Oncology|May 17, 2023
Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world settingOliver Kraskowski, Jan A Stratmann, Marcel Wiesweg, et al.European Journal of Cancer (Oxford, England : 1990)|March 4, 2021
DNA methylation of PTGER4 in peripheral blood plasma helps to distinguish between lung cancer, benign pulmonary nodules and chronic obstructive pulmonary disease patientsLea M Schotten, Kaid Darwiche, Michal Seweryn, et al.European Journal of Radiology|February 22, 2023
Neoadjuvant immune-checkpoint inhibitors in lung cancer - a primer for radiologistsDaria Kifjak, Maximilian J Hochmair, Dagmar Krenbek, et al.Translational Lung Cancer Research|July 17, 2025
Impact of KRAS mutation subtypes on morphological heterogeneity and immune landscape in surgically treated lung adenocarcinomaKlara Torok, Bence Ferencz, Kristiina Boettiger, et al.International Journal of Molecular Sciences|March 25, 2022
The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint InhibitionLuca Hegedüs, Elisabeth Livingstone, Ágnes Bánkfalvi, et al.Scientific Reports|November 30, 2017
Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesotheliomaThomas Klikovits, Paul Stockhammer, Viktoria Laszlo, et al.Scientific Reports|April 3, 2020
Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibitionBahil Ghanim, Anna Rosenmayr, Paul Stockhammer, et al.Journal of Oncology|August 17, 2018
Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53Robert F H Walter, Robert Werner, Michael Wessolly, et al.Oncogene|December 21, 2018
Impact of RAS mutation subtype on clinical outcome-a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancerMarcel Wiesweg, Stefan Kasper, Karl Worm, et al.European Journal of Cancer (Oxford, England : 1990)|April 19, 2021
BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapyMarcel Wiesweg, Cedric Preuß, Julia Roeper, et al.Pageof 27